Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
55.15
+1.01 (+1.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
↗
June 19, 2026
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....
Via
InvestorPlace
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
June 16, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
June 04, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics (NASDAQ:TVTX) Q1 2026 Results Show Record FILSPARI Sales and FSGS Approval, but Revenue and EPS Miss Estimates
↗
May 04, 2026
Via
Chartmill
Travere Therapeutics (NASDAQ:TVTX) Posts Q4 Earnings Beat on Profitability Despite Revenue Miss
↗
February 19, 2026
Via
Chartmill
Topics
Earnings
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
June 02, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
May 27, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters
↗
May 10, 2026
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and pipeline progress.
Via
The Motley Fool
Topics
Regulatory Compliance
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 07, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 06, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 05, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
↗
May 05, 2026
Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.
Via
Benzinga
Travere (TVTX) Q1 2026 Earnings Transcript
↗
May 04, 2026
Travere (TVTX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Travere Therapeutics Reports First Quarter 2026 Financial Results
May 04, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere (TVTX) Q2 2025 Earnings Transcript
↗
May 04, 2026
Travere (TVTX) Q2 2025 Earnings Transcript
Via
The Motley Fool
Travere (TVTX) Q4 2025 Earnings Transcript
↗
May 04, 2026
Travere (TVTX) Q4 2025 Earnings Transcript
Via
The Motley Fool
Travere Therapeutics to Report First Quarter 2026 Financial Results
April 27, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started?
↗
April 20, 2026
Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 14, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
These stocks are moving in today's session
↗
April 14, 2026
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Topics
Artificial Intelligence
Tuesday's session: gap up and gap down stocks
↗
April 14, 2026
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
April 14, 2026
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via
Chartmill
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
April 13, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
March 31, 2026
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to...
Via
MarketMinute
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
March 10, 2026
Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER...
Via
MarketMinute
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
February 19, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
↗
February 17, 2026
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
↗
February 17, 2026
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
